Asgard Therapeutics

Cancer immunotherapy
#Asgard Therapeutics #Biotech #Cancer immunotherapy #Tumour biology

Gene-based immunotherapy could reprogramme tumour cells 

Biotechnology company Asgard Therapeutics is set to announce preclinical results showing its gene-based cancer immunotherapy could reprogramme tumour cells.  The company will present data on AT-108, a first-in-class, off-the-shelf cancer immunotherapy, in an oral presentation at the ASGCT Annual Meeting, held from 11-15 May in Boston,… Read More

#News

#Asgard Therapeutics #Biotech

Asgard Therapeutics appoints Dr Wolfram Brugger as CMO 

Biotechnology company Asgard Therapeutics has appointed Dr Wolfram Brugger as Chief Medical Officer.  Brugger, who has been involved in more than 130 Phase I to III clinical oncology trials across a wide variety of cancer types, has been appointed to strengthen Asgard’s leadership as it prepares to transition… Read More

#News

#Asgard Therapeutics #Cell and gene therapy #Financing #Immuno-oncology #In vivo

€30m raised for first-in-class in vivo cell reprogramming platform

Biotech Asgard Therapeutics has closed a €30 million Series A financing to support the development of its lead programme, AT-108. The company plans to submit an Investigational New Drug (IND) application to the FDA for AT-108 by 2026, expand and reinforce its research and development team, and fuel new reprogramming… Read More

#Business & Investment #News